Information Provided By:
Fly News Breaks for February 25, 2020
CCXI
Feb 25, 2020 | 07:53 EDT
Canaccord analyst Michelle Gilson raised her price target on ChemoCentryx to $64 from $48 following a positive Phase 3 ADVOCATE study evaluating avacopan in ANCA-associated vasculitis. The analyst sees additional opportunity for avacopan beyond vasculitis he notes investor's attention has switched to the company pipeline which is filled with multiple catalysts. Gilson reiterated her Buy rating on ChemoCentryx shares.
News For CCXI From the Last 2 Days
There are no results for your query CCXI